Ilan Uchitel, CAPS Medical - Minimally Invasive Treatment of Solid Tumors | LSI Europe '22

Transcription

Ilan Uchitel  0:05  

My name is Ilan Uchitel, I'm the CEO of CAPS Medical. Thank you for the opportunity to present a company and the amazing technology behind it, which we believe will be making a significant contribution to how so acute boomers are treated in the future. There are over 90 million new cancer cases discovered every year. In cancer therapies, you're always striving to maximize damage to cancer cells, while minimizing damage to the healthy tissue surrounding it. Yet, the subjective objective is extremely elusive. When we're talking about internal organs. At CAPS Medical, we have developed a system that does just that. We're targeting, so tumors selectively precisely by destroying on a cancerous cells from evasive procedures, and sparing the healthy tissue surrounded by these were avoiding many of the life altering side effects of the existing therapies. Our proprietary technology is called and it is based on non thermal atmospheric plasma, and up is a stream of an iris guessed it near room temperature, it doesn't cause thermal damage near future to the tumor, nor to the healthy tissues around it. And up generates reactive oxygen and nitrogen species. Visa no known to selectively cause stress to cancer cells propagating in cancer cell belt by authorities, which in line is triggering an immune response, which is selectively targeting similar cancer skin cells in a cascade response, which means that actually the immune system is the one that has happened the body to destroy the tumor and not the direct contact with our technology. All that is happening, while the healthy tissues around the tissue the tumor is remaining completely intact. So the effectiveness of non thermal plasmas is in destroying various types of cancer is backed by over 15 years of scientific evidence. The problem is that the high energy required to generate plasma causes the existing devices today being too large to be applied inside the body. Unfortunately, this is where they're needed the most. And this is exactly where cubs breakthrough comes in. This is the first technology ever to be able to deliver non thermal plasma internally. Our small diameter flexible catheter can be introduced we work in channel of existing minimally invasive tools, allowing us to deliver the selective therapy directly to the tumor inside the body. Now, this highly selective technology can be delivered as a keyhole procedure without cutting, cheering ablating or calculating and with precise real time monitoring of the amount of energy delivered to the tumor, which is crucial to virt to adopting the technology to various type of cancer. Our system consists of a console, which can be either sold or leased depending on the business model, and a disposable procedure kit, one per procedure, which is our main revenue driver. By the way, as you can see this is completed on thermal on my seven fingers are still placed. So having the small damage and flexible catheter allows us to naturally fit into the minimally invasive echo system putting us in the focus of all the large players. In our vision, we want to deploy the technology throughout the whole body treating tumors, either in the scopic three through two cars, needles, we can assemble it on robotic platforms or even treat it superficially like our competitors are doing. Our initial treatment indication is non muscle invasive bladder cancer, NMI BC. This is the sixth most common cancer in the world, or 1.6 million people suffering from the disease worldwide, with more than 200,000 new cancer cases added annually. What's typical about this disease that is usually just doesn't go away. It's treated and retreated by implementing a resection of the tumor followed by a series of inter vesicle installations. The higher recurrence rate of this disease which can go up to 80% makes NMI BC the highest cost per patient cancer type in the world. So CAPS Medical is a pioneer in treating tumors inside the body using NTAP. In our clinical study, we have achieved an outstanding results in which all the patients were treated and successfully removing all the treated tumors following a single treatment. This is the representing case of a patient suffering from three tumors that were treated using NTAP. As, as you can see, tumors have been completely dedicated without any damage to the healthy tissue, as was demonstrated in our continue a follow up. This is a very typical result, and it came across similar to in all between the patients. Now here we can see the amazing difference between and the advantage of NTAP that preserves healthy tissue and the standard of care, which by the way, also removes the tumor. But you can see the amount of scarring and damage to the vital tissue that will never grow back. That is done during the process. And this is exactly the same activity that I was talking about in previous slides. For NMI, DC, for NBC our procedures delivered to southern oscilloscope, by utilizing existing CPT codes. Our immediate goal is to replace the resection and the associated side effects, then we're taking this procedure and we're moving it out to the outpatient basis. By that we're boosting reimbursement, reducing the cost of treatment and setting up the right platform to use the immune effects that our technology delivers to tackle also the recurrence rate and the disease progression. The competitive landscape is actually wide open. As I mentioned the thermal technologies today's are destroying vital tissue. The installation efficacy enhancers are not replacing this resection. Other non thermal plasma technologies are too large to be applied inside the body. While the pharma solutions are expensive and applicable only to the high grade cases which are a relatively limited. Capital spending to begin our pivotal study of 100 patients in the middle of 2023. Based on the progress achieved so far, we're now accelerating the development towards introducing this technology towards other indications including lung cancer, breast cancer, glioblastoma, and additional indications. So far, we haven't encountered any resistance to enter treatment in any of the variety of solid tumors treated in our preclinical studies. Our work plan has CE mark slated for 2025 and FDA clearance in 2026. We have one licensed family of veterans from the Israeli Technion that came up with this brilliant idea and additional eight families of patents in various stages of applications worldwide. Our leadership team has extensive entrapreneurship and executive experience in the medical device field and the proven track record of the leadership position in multiple global companies. The team is supported by a wide panel of medical and scientific advisors with deep understanding of cancer care and outstanding market access. Up to date since our inception in 2010, the company has raised $10 million, mostly from private investors, one strategic and non dilutive grants, we're now seeking to raise $30 million a the proceeds from which will be used to conduct the pivotal study and to fund the company's operation throughout the CE and the FDA clearance. So just to sum things up, our clinical results point to our technology been a selective a quality treatment, which we see been variable to for multiple additional indications. We have a huge oncology market potential with clear goal to market. Our leadership team has vast experience in bringing similar companies to market and commercialization. And we are supported by a panel of world renowned experts with collaboration with many leading academic institutions. So thank you for the opportunity to present this emerging technology. I will be here to the rest of the day and we'll be glad to speak to everybody